课题基金 / 基金详情

CD38+ T cells in malaria immuno-suppression

CD38+ T cells in malaria immuno-suppression
CD38 T 细胞在疟疾免疫抑制中的作用
批准号:
nhmrc : 181614
负责人:
Prof Magdalena Plebanski
金额:
$13.36万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2002
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2002-01-01 至 2004-12-31

项目摘要

项目成果

Prof Magdalena Plebanski的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Malaria is characterised by defective T cell responses, particularly suppressed T cell growth. T cells are critical to malaria protection and defective immune responses are likely to benefit the parasite. We want to find out how immune-responses are turned off in malaria, so that then we can do something about this, and help fight off the parasite. Malaria kills over 2 million children each year and there is no effective vaccine. We have two important clues as what may be happenning to cause suppressed T cell growth during malaria infection. Firstly, we found a massive increase in T cells expressing a surface molecule called CD38 duirng infection. Increases in these cells correlated with decreases in the ability of the T cells from the animals to grow. Indeed, other researchers had observed that in mice CD38 T cells can suppress immunity. Secondly, we hypothesized that they may be responsible for the impaired T cell reactivity observed during acute malaria, and the general poor state of immune responses in humans living in areas where they are being constantly infected by the parasite. Indeed, when we removed cells expressing CD38 from blood cells from such individuals, these 'recovered' and were able to grow much better in our assays. Therefore we propose that CD38 T cells are importnat mediators of malaria immuno-suppression. We now want to understand how the parasite induces these CD38 T cells, and how their ability to suppress T cell responses can benefit the parasite. Knowing this we aim to develop vaccines which can avoid being turned off by malaria. T cells expressing CD38 are also increased in cancer and acute viral disease, such as late stage HIV. Understanding their role in malaria will also give us new clues to fight such diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Innovative immune-based therapies and diagnostics: using nanotechnology for personalized medicine
  • 批准号:
    nhmrc : GNT1154850
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $79.23万
  • 财政年份:
    2019
  • 负责人:
    Prof Magdalena Plebanski
  • 依托单位:
Use novel properties of nanoparticles to engineer and progress to the clinic 2nd generation therapeutics to tackle major human diseases including cancer, malaria and asthma
  • 批准号:
    nhmrc : GNT1059409
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $60.14万
  • 财政年份:
    2014
  • 负责人:
    Prof Magdalena Plebanski
  • 依托单位:
Immune imprinting by nanoparticles and vaccines: new principles and translation into the clinic
  • 批准号:
    nhmrc : 1059409
  • 项目类别:
    Research Fellowships
  • 资助金额:
    $42.08万
  • 财政年份:
    2014
  • 负责人:
    Prof Magdalena Plebanski
  • 依托单位:
Biodegradable immuno-therapeutic nanoparticles
  • 批准号:
    DP0986357
  • 项目类别:
    Discovery Projects
  • 资助金额:
    $29.08万
  • 财政年份:
    2009
  • 负责人:
    Prof Magdalena Plebanski
  • 依托单位:
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
  • 批准号:
    82371634
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵福军
  • 依托单位:
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
  • 批准号:
    82371801
  • 项目类别:
    面上项目
  • 资助金额:
    47.00万元
  • 批准年份:
    2023
  • 负责人:
    周海波
  • 依托单位:
脐带间充质干细胞微囊联合低能量冲击波治疗神经损伤性ED的机制研究
  • 批准号:
    82371631
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    卢慕峻
  • 依托单位: